The impact of the molecular profile and treatment of older and fragile patients with relapsed/refractory FLT3-mutated AML
In this MEDtalk, Marina Konopleva, Professor at Montefiore Einstein Cancer Center in New York, gives her perspective on the impact of the molecular profile for patients with relapsed/refractory AML. You can also hear her treatment recommendation for older and fragile patients with relapsed/refractory FLT3-mutated AML and what we can expect during the next one to three years.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.